Changes in Beneficial Ownership · 4
Liquidia Corporation
LQDANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2627530-3_4seq1.xml
Filing details
- Report period
- 2026-10-09
- Issuer
- Liquidia Corp
- Issuer CIK
- 0001819576
- Trading symbol
- LQDA
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- JEFFS ROGER
- Reporting owner CIK
- 0001231615
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-09 | M · Form 4 | 13,833[F2] | A | [F1] | 1,144,259[F3] | D |
| Common Stock | 2026-10-09 | M · Form 4 | 14,333[F4] | A | [F1] | 1,158,592[F3] | D |
| Common Stock | 2026-10-12 | S · Form 4[F5] | 32,744[F6] | D | 28.48 | 1,125,848[F3] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 46,595 | I | See footnote[F7] |
| Common Stock | 1,041,667 | I | See footnote[F8] |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Units | [F1] | 2026-10-09 | M · Form 4 | 13,833 | D | 0 | [F1] | [F1] | Common Stock | 13,833 | 69,168 | D |
| Performance Stock Units | [F1] | 2026-10-09 | M · Form 4 | 14,333 | D | 0 | [F1] | [F1] | Common Stock | 14,333 | 128,996 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Performance stock units ("PSUs") convert into common stock on a one-for-one basis.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
- F2
- On January 11, 2024, the Reporting Person was granted 221,338 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 152,170 have vested as of the date of this Form 4.↩ 1
- F3
- Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4.↩ 1↩ 2↩ 3
- F4
- On January 11, 2025, the Reporting Person was granted 229,327 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 100,331 have vested as of the date of this Form 4.↩ 1
- F5
- Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.↩ 1
- F6
- These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025.↩ 1
- F7
- The securities are held by Roger A. Jeffs Living Trust UAD 2/29/2000 (the "Trust"). The Reporting Person is the trustee of the Trust.↩ 1
- F8
- The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity.↩ 1
Signature 1
- Signed
- /s/ Roger Jeffs
- Date
- 2026-10-13
Company context
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug approved in 2025 for the treatment of PAH. YUTREPIA is currently under development for other indications, including SSc-RP and PH-COPD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. To learn more about Liquidia, please visit www.liquidia.com.